443 related articles for article (PubMed ID: 7887660)
1. Treatment of advanced mycosis fungoides and Sézary syndrome with continuous infusions of methotrexate followed by fluorouracil and leucovorin rescue.
Schappell DL; Alper JC; McDonald CJ
Arch Dermatol; 1995 Mar; 131(3):307-13. PubMed ID: 7887660
[TBL] [Abstract][Full Text] [Related]
2. Prognostic factors in erythrodermic mycosis fungoides and the Sézary syndrome.
Kim YH; Bishop K; Varghese A; Hoppe RT
Arch Dermatol; 1995 Sep; 131(9):1003-8. PubMed ID: 7661601
[TBL] [Abstract][Full Text] [Related]
3. Treatment of mycosis fungoides lymphoma: effectiveness of infusions of methotrexate followed by oral citrovorum factor.
McDonald CJ; Bertino JR
Cancer Treat Rep; 1978 Jul; 62(7):1009-14. PubMed ID: 308391
[TBL] [Abstract][Full Text] [Related]
4. Bexarotene therapy for mycosis fungoides and Sézary syndrome.
Abbott RA; Whittaker SJ; Morris SL; Russell-Jones R; Hung T; Bashir SJ; Scarisbrick JJ
Br J Dermatol; 2009 Jun; 160(6):1299-307. PubMed ID: 19222457
[TBL] [Abstract][Full Text] [Related]
5. Advanced mycosis fungoides: chemotherapy with etoposide, methotrexate, bleomycin, and prednimustine.
Doberauer C; Ohl S
Acta Derm Venereol; 1989; 69(6):538-40. PubMed ID: 2481928
[TBL] [Abstract][Full Text] [Related]
6. Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression.
Kim YH; Liu HL; Mraz-Gernhard S; Varghese A; Hoppe RT
Arch Dermatol; 2003 Jul; 139(7):857-66. PubMed ID: 12873880
[TBL] [Abstract][Full Text] [Related]
7. Retrospective 5-year review of 131 patients with mycosis fungoides and Sézary syndrome seen at the National Skin Centre, Singapore.
Tan ES; Tang MB; Tan SH
Australas J Dermatol; 2006 Nov; 47(4):248-52. PubMed ID: 17034466
[TBL] [Abstract][Full Text] [Related]
8. Cisplatin, fluorouracil, and L-leucovorin induction chemotherapy for locally advanced head and neck cancer: the M.D. Anderson Cancer Center experience.
Papadimitrakopoulou VA; Dimery IW; Lee JJ; Perez C; Hong WK; Lippman SM
Cancer J Sci Am; 1997; 3(2):92-9. PubMed ID: 9099459
[TBL] [Abstract][Full Text] [Related]
9. A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil.
Hsu CH; Cheng AL; Hsu C; Yang CH; Lu YS; Lin CC; Bu CF; Yeh KH
Anticancer Res; 2002; 22(6B):3621-7. PubMed ID: 12552966
[TBL] [Abstract][Full Text] [Related]
10. Mitoxantrone, 5-fluorouracil, and high dose leucovorin (NFL) versus intravenous cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in first-line chemotherapy for patients with metastatic breast carcinoma: a randomized phase II trial.
Hainsworth JD; Jolivet J; Birch R; Hopkins LG; Greco FA
Cancer; 1997 Feb; 79(4):740-8. PubMed ID: 9024712
[TBL] [Abstract][Full Text] [Related]
11. Interferon and low dose methotrexate improve outcome in refractory mycosis fungoides/Sézary syndrome.
Avilés A; Nambo MJ; Neri N; Castañeda C; Cleto S; Gonzalez M; Huerta-Guzmán J
Cancer Biother Radiopharm; 2007 Dec; 22(6):836-40. PubMed ID: 18158775
[TBL] [Abstract][Full Text] [Related]
12. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
Klaassen U; Wilke H; Seeber S
Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the efficacy of the combination of oral bexarotene and methotrexate for the treatment of early stage treatment-refractory cutaneous T-cell lymphoma.
Kannangara AP; Levitan D; Fleischer AB
J Dermatolog Treat; 2009; 20(3):169-76. PubMed ID: 19016373
[TBL] [Abstract][Full Text] [Related]
14. Treatment of late-stage Sézary syndrome with 2-Chlorodeoxyadenosine.
Bouwhuis SA; el-Azhary RA; McEvoy MT; Gibson LE; Habermann TM; Witzig TE; Pittelkow MR
Int J Dermatol; 2002 Jun; 41(6):352-6. PubMed ID: 12100691
[TBL] [Abstract][Full Text] [Related]
15. Isotretinoin and cutaneous helper T-cell lymphoma (mycosis fungoides).
Kessler JF; Jones SE; Levine N; Lynch PJ; Booth AR; Meyskens FL
Arch Dermatol; 1987 Feb; 123(2):201-4. PubMed ID: 2949706
[TBL] [Abstract][Full Text] [Related]
16. Applying the new TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sézary syndrome in primary cutaneous marginal zone lymphoma.
Gerami P; Wickless SC; Rosen S; Kuzel TM; Ciurea A; Havey J; Guitart J
J Am Acad Dermatol; 2008 Aug; 59(2):245-54. PubMed ID: 18486274
[TBL] [Abstract][Full Text] [Related]
17. Clinical stage IA (limited patch and plaque) mycosis fungoides. A long-term outcome analysis.
Kim YH; Jensen RA; Watanabe GL; Varghese A; Hoppe RT
Arch Dermatol; 1996 Nov; 132(11):1309-13. PubMed ID: 8915308
[TBL] [Abstract][Full Text] [Related]
18. Total skin electron beam therapy in mycosis fungoides. Our experience from 1985 to 1999.
Rampino M; Ragona R; Monetti U; Mussano A; Guarneri A; Sannazzari GL
Radiol Med; 2002; 103(1-2):108-14. PubMed ID: 11859306
[TBL] [Abstract][Full Text] [Related]
19. [Chronotherapy with high dose carboplatin, 5-fluorouracil and leucovorin in advanced colorectal carcinoma].
Popov I; Jelić S; Radosavljević D; Nikolić-Tomasević A
Srp Arh Celok Lek; 1998; 126(9-10):355-61. PubMed ID: 9863407
[TBL] [Abstract][Full Text] [Related]
20. Durable clinical, cytogenetic, and molecular remissions after allogeneic hematopoietic cell transplantation for refractory Sezary syndrome and mycosis fungoides.
Molina A; Zain J; Arber DA; Angelopolou M; O'Donnell M; Murata-Collins J; Forman SJ; Nademanee A
J Clin Oncol; 2005 Sep; 23(25):6163-71. PubMed ID: 16135483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
